Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | RGS4 | P49798 | 1/20 | 0.32 |
| ▸ | RGS8 | P57771 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206771 | 0.74 | — | — | |
| SCHEMBL14492003 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL16660209 | 0.67 | — | — | |
| SCHEMBL13208008 | 0.60 | — | — | |
| SCHEMBL6897322 | 0.59 | NFE2L2 (0.35) | NFE2L2 | |
| SCHEMBL18885973 | 0.59 | ALDH1A1 (0.38) | NFE2L2HCAR3 | |
| SCHEMBL22108991 | 0.58 | RGS4 (0.31) | RGS4RGS8 | |
| SCHEMBL11521515 | 0.57 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL22108755 | 0.57 | RGS4 (0.30) | RGS4RGS8 | |
| SCHEMBL12595108 | 0.57 | TDP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9566278-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566278-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | NFE2L2 4133/4885RGS4 791/4885RGS8 425/4885 |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NFE2L2 2747/4885RGS4 1976/4885RGS8 1189/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | NFE2L2 880/4885RGS4 4222/4885RGS8 4458/4885 |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | NFE2L2 2747/4885RGS4 1976/4885RGS8 1189/4885 |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | NFE2L2 711/4885RGS4 1236/4885RGS8 814/4885 |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | NFE2L2 2747/4885RGS4 1976/4885RGS8 1189/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | NFE2L2 1876/4885RGS4 2700/4885RGS8 3025/4885 |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NFE2L2 2747/4885RGS4 1976/4885RGS8 1189/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NFE2L2 2747/4885RGS4 1976/4885RGS8 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.